Can you discuss the complications of excessive glucocorticoid exposure in children, adolescents, and adults, and the impact on cardiac and metabolic morbidities? What is the rational for looking for alternatives to glucocorticoid therapy for CAH?
Can you discuss the complications of excessive glucocorticoid exposure in children, adolescents, and adults, and the impact on cardiac and metabolic morbidities? What is the rational for looking for alternatives to glucocorticoid therapy for CAH?
Associate Professor, Institute of Molecular Medicine Feinstein Institutes for Medical Research Emerita Professor, Pediatrics Donald and Barbara Zucker School of Medicine Hofstra/Northwell New Hyde Park, NY
